Evommune (NYSE:EVMN) Insider Sells $324,711.09 in Stock

Evommune, Inc. (NYSE:EVMN) insider Gregory Moss sold 14,223 shares of Evommune stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $22.83, for a total transaction of $324,711.09. Following the completion of the transaction, the insider directly owned 60,835 shares in the company, valued at $1,388,863.05. This trade represents a 18.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Evommune Price Performance

Shares of NYSE:EVMN opened at $19.78 on Thursday. The company has a 50 day moving average price of $23.98. The company has a market capitalization of $712.62 million and a PE ratio of -2.08. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $33.20.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. As a group, sell-side analysts predict that Evommune, Inc. will post -2.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Evommune

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Evommune during the fourth quarter valued at about $34,000. Strs Ohio acquired a new position in shares of Evommune during the first quarter valued at about $41,000. The Manufacturers Life Insurance Company acquired a new position in shares of Evommune during the fourth quarter valued at about $179,000. XTX Topco Ltd acquired a new position in shares of Evommune during the fourth quarter valued at about $321,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Evommune during the fourth quarter valued at about $335,000.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on EVMN shares. Stifel Nicolaus started coverage on shares of Evommune in a report on Friday, May 1st. They issued a “buy” rating and a $54.00 target price on the stock. Morgan Stanley boosted their target price on shares of Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Oppenheimer started coverage on shares of Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 target price on the stock. Evercore restated an “outperform” rating and issued a $55.00 target price on shares of Evommune in a report on Tuesday, February 10th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $48.00 target price on shares of Evommune in a report on Friday, April 10th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $49.25.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.